Core for Life - a new European alliance in biomedical research: http://t.co/Hvv6P88kRt
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from vzw VIB. read more
Trinean NV today announced the appointment of Philippe Stas as it’s new CEO, succeeding Dr. Marc Zabeau, who remains a member of the board of directors. Simultaneously, Trinean announced that the company has secured 2.7 million euro of growth financing provided by its existing investors. read more
Complix NV, a biopharmaceutical company focused on the discovery and development of Alphabodies, a unique class of protein therapeutics that are active against both extracellular and intracellular disease targets, announces that it will provide an update on new developments with its Alphabody™ platform at the Biologics Partnering Forum in Boston, MA on 29 April 2012. read more
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, and PLUS Diagnostics today announced that they have entered into an agreement to co-promote MDxHealth’s ConfirmMDxTM for Prostate Cancer test in the United States. read more
Ablynx [Euronext Brussels: ABLX] today announced that Boehringer Ingelheim has submitted a Clinical Trials Application (CTA) to the European regulatory authorities to start a Phase I clinical trial with a Nanobody® for the treatment of Alzheimer's disease. The Nanobody has been developed as part of the collaboration signed between Ablynx and Boehringer and the event triggers a €1 million milestone payment to Ablynx. read more
While the practical performance of a quantitative PCR experiment is relatively straightforward, many users struggle with the data-analysis. It is therefore not surprising that user-friendly software tools emerged and became indispensible for data handling. Such tools help applying validated procedures and guide the experimenter to highest quality results. read more
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces that it has been granted the first patent covering its novel NHance™ technology. read more